BPC-157, GHK-Cu, and TB-500 are research-only compounds with no FDA-approved dosing. The ranges below are commonly cited in community and grey-market sources and anecdotal — they are not medically established. "GLOW" is a marketing name, and the blend has no dedicated dosing studies. This is educational context, not a protocol.
The short answer
No validated dose exists for the "GLOW" blend, at any level of the question: no component has a human dose-finding study, no ratio of the three peptides has ever been compared against another, and the only controlled data on any part of the combination — BPC-157 plus TB-500 in rat tendon repair — found the pairing no better than one agent alone (Biçer et al., Jt Dis Relat Surg 2026). What follows reports the community patterns for the individual components and the structural reason a fixed blend cannot honor them.
Commonly cited community pattern
When the components are discussed individually in community logs and vendor materials, the frequently repeated ranges are:
- BPC-157: ~250–500 mcg, once or twice daily.
- TB-500: ~2–2.5 mg once or twice weekly as a "loading" phase, then roughly weekly.
- GHK-Cu: ~1–2 mg per day when injected — though the compound's actual human evidence base is topical creams, not injections (Pickart & Margolina, Int J Mol Sci 2018).
These are anecdotal reference points with no clinical validation behind any of them, individually or combined.
Three schedules, one vial
A pre-mixed blend turns three dosing questions into one impossible one. There is no standardized GLOW ratio — vendors sell different total amounts and different splits (for example 10/10/10 mg or weighted toward one peptide), and because no study of the trio exists, no ratio can claim superiority. The community schedules also conflict: daily BPC-157, weekly-ish TB-500, daily GHK-Cu. Any draw from a fixed mixture delivers all three in the vendor's proportion, so at least one component is always off its own cited cadence. The "protocol" a blend user follows is, in practice, a packaging decision made by whoever filled the vial.
How a blend is administered
The vial arrives as lyophilized powder, reconstituted with bacteriostatic water before subcutaneous injection.
- Each peptide's mass divided by the diluent volume sets its concentration — the Peptide Calculator maps the arithmetic, though with three peptides per vial every draw contains all of them.
- Doses are read as syringe units of volume, an error-prone step that a three-peptide solution makes harder to reason about.
- Stability of this particular mixture — including a copper-complexed peptide alongside two others — has never been characterized; sterile handling and refrigeration after reconstitution matter.
Why oversight matters
None of these compounds is an approved medicine. BPC-157 sits on the FDA's compounding safety-risk list, where the agency states it lacks sufficient information to know whether the drug would cause harm in humans (FDA); TB-500 is prohibited in sport at all times (WADA S2.3); and GHK-Cu's safety record was built with creams, not needles. Precision about micrograms is misplaced when the ratio, the stability, and the combination's premise are all untested — the one study that examined stacking these healing peptides found no additive benefit. A qualified clinician can evaluate the underlying goal, whether that is injury recovery or skin quality, against options that have actual evidence. The ranges above describe online consensus, not a recommendation.
Sport & Anti-Doping Warning
This combination includes TB-500 and BPC-157, both of which are prohibited in sport; adding GHK-Cu does not change their anti-doping status and can increase the experimental nature of the stack.
Anti-doping rules focus on the presence of any prohibited substance, so a multi-peptide vial that contains BPC-157 or TB-500 still triggers violations.